<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095978</url>
  </required_header>
  <id_info>
    <org_study_id>P11-979</org_study_id>
    <nct_id>NCT01095978</nct_id>
  </id_info>
  <brief_title>Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine</brief_title>
  <acronym>KLARAINE</acronym>
  <official_title>Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the relief of symptoms, tolerability, and compliance of treatment with KlacidÂ®
      sustained release (SR) at a dose of 1000 mg once daily in patients with acute tracheitis,
      acute tracheobronchitis, acute bronchitis, or in patients with acute exacerbation of chronic
      bronchitis or mild community-acquired pneumonia.

      This postmarketing observational study is non-interventional and is being conducted in a
      prospective, single-arm, single-country, multicenter format.

      Klacid SR will be prescribed in usual manner in accordance with the terms of the local market
      authorization with regards to dose, population, and indication as well as with local
      guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The postmarketing observational study is observational in nature. Its follow-up is not
      interventional and is left to the judgment of each physician during the observational period,
      which defines the survey for each patient. Follow-up of patients should enable two patient
      visits during this period.

      The screening/inclusion visit (Visit 1) will be performed when the decision for Klacid SR
      therapy in a daily dose of 1000 mg is made. The second visit of the patient will occur 10 -
      16 days from the screening/inclusion Visit (upon physician's decision). The physician can
      change the numbers and time of the visits. As a result, failure to meet these suggested dates
      will not constitute a breach of the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
    <description>Body temperature was measured at Visit 1 (initial visit) and at Visit 2 (approximately 10 to 16 days later, or as defined by the treating physician). Fever was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The presence or absence of fever is reported at Visit 1 and 2 for all participants and by age subgroups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cough and Its Character</measure>
    <time_frame>Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
    <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence of cough and the type of cough (productive, irritating, or both) was determined based on the clinical judgment of the treating physician. The presence or absence of cough are reported at Visits 1 and 2 for all participants and by age subgroups. For those participants who had a cough at Visit 1, the number of participants whose original type of cough subsequently resolved at Visit 2 is also presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyspnoea</measure>
    <time_frame>Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
    <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence or absence of dyspnoea (difficulty breathing) was determined based on the clinical judgment of the treating physician and is reported for all participants and by age subgroup at Visit 1 and Visit 2. For participants with dyspnoea at Visit 1, whether the dyspnoea occurred at rest, after exercise, or both are reported. For those with dyspnoea at Visit 1, the number of participants whose original type of dyspnoea subsequently resolved at Visit 2 is noted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Auscultation Findings</measure>
    <time_frame>Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
    <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence of abnormal breathing sounds such as wheezing or crackles was determined by the treating physician using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck, or abdomen) combined with their clinical judgment. Results are reported at Visit 1 and Visit 2 for all participants and by age subgroups. For participants with abnormal breathing sounds at Visit 1, resolution was noted at Visit 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chest Xray - Necessary for Verification of the Diagnosis of Pneumonia , Community-acquired Pneumonia</measure>
    <time_frame>Visit 1 (Initial visit)</time_frame>
    <description>Chest xrays were taken at Visit 1 to determine the presence of absence of community-acquired pneumonia. Findings are presented for all participants and by age subgroups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Previous Prescription of Other Antibiotic (Answer Whether Klacid SR is Given as the First or as Second Antibiotic)</measure>
    <time_frame>Visit 1 (Initial visit)</time_frame>
    <description>Treating physicians were asked if Klacid SR was the first or second antibiotic prescribed to treat the participant. Results are presented for all participants and age subgroups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic Response</measure>
    <time_frame>Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
    <description>Therapeutic response (yes or no) was determined by the treating physician at Visit 2 based on the disappearance or significant alleviation of symptoms and regression of chest xray findings. The data are summarized by total number of participants and by age subgroups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
    <description>The number of participants experiencing adverse events, including serious adverse events, adverse events leading to study discontinuation, or adverse events leading to a dose reduction/temporarily stopping medication are summarized. See Reported Adverse Events for additional details.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance (Was the Dosage and Duration of Therapy Followed or Not; if Not - Explain the Reason)</measure>
    <time_frame>Visit 2 (10th-16th day or any other day after Inclusion Visit defined by physician)</time_frame>
    <description>Compliance was assessed by asking physicians if participants took their medication as directed. If participants did not take their medication as directed, physicians were asked to give the reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Termination of Treatment</measure>
    <time_frame>Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
    <description>The number of participants who discontinued treatment is summarized.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2822</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Acute upper respiratory tract diseases, bronchitis, pneumonia</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin (Klacid SR)</intervention_name>
    <description>Klacid SR in a dose of 1000 mg once daily</description>
    <arm_group_label>Acute upper respiratory tract diseases, bronchitis, pneumonia</arm_group_label>
    <other_name>Biaxin</other_name>
    <other_name>Abbotic</other_name>
    <other_name>Biclar</other_name>
    <other_name>Klacid</other_name>
    <other_name>Klaricid</other_name>
    <other_name>Zeclar</other_name>
    <other_name>Clarithromycin</other_name>
    <other_name>Klacid SR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consulting rooms of general practitioners, pulmonologists, and allergologists and centers
        with experience in the treatment of patients with acute upper respiratory tract diseases,
        acute bronchitis or acute exacerbation of chronic bronchitis or mild community-acquired
        pneumonia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men, women 18 years with

               1. Acute tracheitis.

               2. Acute tracheobronchitis.

               3. Acute bronchitis.

               4. Mild community-acquired pneumonia.

               5. Acute exacerbation of chronic bronchitis.

          -  To whom decision to initiate Klacid SR therapy in a dose of 1000 mg has been made by
             physician.

        Exclusion Criteria:

          -  Known hypersensitivity to macrolide antibiotics

          -  Documented renal impairment (creatinine clearance under 30 ml/min)

          -  Concomitant therapy with the following drugs: astemizole, cisapride, pimozide,
             terfenadine and ergotamine or dihydroergotamine

          -  Pregnancy

          -  Breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Magdik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Laboratories S.A., Ukraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29842</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29848</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30028</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30046</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30047</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30049</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30059</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30074</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30080</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30099</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30535</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30572</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30574</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30575</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30576</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30577</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30578</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30579</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30580</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30581</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30582</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30583</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30589</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30590</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30622</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30623</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30050</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30051</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30054</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30057</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30060</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30066</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30071</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30073</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30573</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30584</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30585</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30600</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30601</name>
      <address>
        <city>Donetsk</city>
        <zip>83000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30586</name>
      <address>
        <city>Donetsk</city>
        <zip>83112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30587</name>
      <address>
        <city>Donetsk</city>
        <zip>83112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30588</name>
      <address>
        <city>Donetsk</city>
        <zip>83112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29840</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30052</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30056</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30058</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30065</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30067</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30075</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30076</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30078</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30079</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30096</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30102</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30616</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30617</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30624</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30625</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30626</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30627</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30628</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30632</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30633</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40761</name>
      <address>
        <city>Kharkov</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30027</name>
      <address>
        <city>Kiev</city>
        <zip>01000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30097</name>
      <address>
        <city>Kiev</city>
        <zip>01004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30098</name>
      <address>
        <city>Kiev</city>
        <zip>01004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30100</name>
      <address>
        <city>Kiev</city>
        <zip>01004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30614</name>
      <address>
        <city>Kiev</city>
        <zip>01004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30615</name>
      <address>
        <city>Kiev</city>
        <zip>01004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30101</name>
      <address>
        <city>Kiev</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 22142</name>
      <address>
        <city>Kiev</city>
        <zip>01033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30553</name>
      <address>
        <city>Kiev</city>
        <zip>01033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30554</name>
      <address>
        <city>Kiev</city>
        <zip>01033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30555</name>
      <address>
        <city>Kiev</city>
        <zip>01033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30556</name>
      <address>
        <city>Kiev</city>
        <zip>01033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30557</name>
      <address>
        <city>Kiev</city>
        <zip>01033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30558</name>
      <address>
        <city>Kiev</city>
        <zip>01033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30061</name>
      <address>
        <city>Kiev</city>
        <zip>02094</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30533</name>
      <address>
        <city>Kiev</city>
        <zip>03026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30534</name>
      <address>
        <city>Kiev</city>
        <zip>03026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30591</name>
      <address>
        <city>Kiev</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30592</name>
      <address>
        <city>Kiev</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30593</name>
      <address>
        <city>Kiev</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30069</name>
      <address>
        <city>Kiev</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30537</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30538</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30539</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30540</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29839</name>
      <address>
        <city>Kiev</city>
        <zip>04074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30531</name>
      <address>
        <city>Kremenchug</city>
        <zip>39600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30532</name>
      <address>
        <city>Kremenchug</city>
        <zip>39600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40759</name>
      <address>
        <city>Kyiv</city>
        <zip>22666</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40760</name>
      <address>
        <city>Kyiv</city>
        <zip>22666</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30604</name>
      <address>
        <city>Lugansk</city>
        <zip>91000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30605</name>
      <address>
        <city>Lugansk</city>
        <zip>91000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30606</name>
      <address>
        <city>Lugansk</city>
        <zip>91000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30559</name>
      <address>
        <city>Lvov</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30561</name>
      <address>
        <city>Lvov</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30562</name>
      <address>
        <city>Lvov</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30563</name>
      <address>
        <city>Lvov</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30564</name>
      <address>
        <city>Lvov</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29948</name>
      <address>
        <city>Odesa</city>
        <zip>65000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30055</name>
      <address>
        <city>Odesa</city>
        <zip>65000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30062</name>
      <address>
        <city>Odesa</city>
        <zip>65000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30594</name>
      <address>
        <city>Odesa</city>
        <zip>65000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30595</name>
      <address>
        <city>Odesa</city>
        <zip>65000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29838</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30044</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30045</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30063</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30126</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30618</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30619</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30620</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30621</name>
      <address>
        <city>Poltava</city>
        <zip>Poltava</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30072</name>
      <address>
        <city>Simferopol'</city>
        <zip>95000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30629</name>
      <address>
        <city>Vynnytsya</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30631</name>
      <address>
        <city>Vynnytsya</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30190</name>
      <address>
        <city>Yevpatoriya</city>
        <zip>97400</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30068</name>
      <address>
        <city>Zaporizhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30565</name>
      <address>
        <city>Zaporizhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30566</name>
      <address>
        <city>Zaporizhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30567</name>
      <address>
        <city>Zaporizhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30568</name>
      <address>
        <city>Zaporizhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30570</name>
      <address>
        <city>Zaporizhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <results_first_submitted>May 17, 2011</results_first_submitted>
  <results_first_submitted_qc>May 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2011</results_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Irina Magdik, Medical Director</name_title>
    <organization>Abbott Laboratories S.A., Ukraine</organization>
  </responsible_party>
  <keyword>Klacid SR</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Respiratory tract infections</keyword>
  <keyword>Bronchitis</keyword>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Tracheitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 2822 participants enrolled, 22 were excluded from analysis for the following reasons: No baseline data (11), did not meet inclusion criteria (7), missing or inconsistent inclusion/final data (2), and no Klacid SR treatment (2). The per-protocol population consists of 2800 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Klacid SR</title>
          <description>Participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2822"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2819"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not take Klacid SR</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Klacid SR</title>
          <description>The per-protocol population (2800 participants) with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2800"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Based on the per-protocol population (2800 participants).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.41" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Based on the per-protocol population (2800 participants).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 to 34 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to 84 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85 years or older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>The gender of the participants was not collected in this study.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Based on the per-protocol population (2800 participants).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Body Temperature</title>
        <description>Body temperature was measured at Visit 1 (initial visit) and at Visit 2 (approximately 10 to 16 days later, or as defined by the treating physician). Fever was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The presence or absence of fever is reported at Visit 1 and 2 for all participants and by age subgroups.</description>
        <time_frame>Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
        <population>The per-protocol population was analyzed. Visit 2 results are shown for those who had fever at Visit 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
          <group group_id="O2">
            <title>Klacid SR (18 to 64 Years of Age)</title>
            <description>Participants 18 to 64 years of age.</description>
          </group>
          <group group_id="O3">
            <title>Klacid SR (65 Years of Age or Older)</title>
            <description>Participants 65 years of age or older.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature</title>
          <description>Body temperature was measured at Visit 1 (initial visit) and at Visit 2 (approximately 10 to 16 days later, or as defined by the treating physician). Fever was defined as body temperature greater than or equal to 37 degrees Celsius/98.6 Fahrenheit. The presence or absence of fever is reported at Visit 1 and 2 for all participants and by age subgroups.</description>
          <population>The per-protocol population was analyzed. Visit 2 results are shown for those who had fever at Visit 1.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
                <count group_id="O2" value="2604"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: No fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Fever present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2617"/>
                    <measurement group_id="O2" value="2434"/>
                    <measurement group_id="O3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Fever resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1780"/>
                    <measurement group_id="O2" value="1655"/>
                    <measurement group_id="O3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Fever still present at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="837"/>
                    <measurement group_id="O2" value="779"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cough and Its Character</title>
        <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence of cough and the type of cough (productive, irritating, or both) was determined based on the clinical judgment of the treating physician. The presence or absence of cough are reported at Visits 1 and 2 for all participants and by age subgroups. For those participants who had a cough at Visit 1, the number of participants whose original type of cough subsequently resolved at Visit 2 is also presented.</description>
        <time_frame>Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
          <group group_id="O2">
            <title>Klacid SR (18 to 64 Years of Age)</title>
            <description>Participants 18 to 64 years of age.</description>
          </group>
          <group group_id="O3">
            <title>Klacid SR (65 Years of Age or Older)</title>
            <description>Participants 65 years of age or older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cough and Its Character</title>
          <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence of cough and the type of cough (productive, irritating, or both) was determined based on the clinical judgment of the treating physician. The presence or absence of cough are reported at Visits 1 and 2 for all participants and by age subgroups. For those participants who had a cough at Visit 1, the number of participants whose original type of cough subsequently resolved at Visit 2 is also presented.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
                <count group_id="O2" value="2604"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: Did not have cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Did not have cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1813"/>
                    <measurement group_id="O2" value="1702"/>
                    <measurement group_id="O3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Had irritating cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1671"/>
                    <measurement group_id="O2" value="1563"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Had irritating cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="220"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Had productive cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1011"/>
                    <measurement group_id="O2" value="931"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Had productive cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="749"/>
                    <measurement group_id="O2" value="682"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Had both types of cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Had both types of cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had any cough at Visit 1 and resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1712"/>
                    <measurement group_id="O2" value="1609"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Irritating cough resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1438"/>
                    <measurement group_id="O2" value="1348"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Productive cough resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="261"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dyspnoea</title>
        <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence or absence of dyspnoea (difficulty breathing) was determined based on the clinical judgment of the treating physician and is reported for all participants and by age subgroup at Visit 1 and Visit 2. For participants with dyspnoea at Visit 1, whether the dyspnoea occurred at rest, after exercise, or both are reported. For those with dyspnoea at Visit 1, the number of participants whose original type of dyspnoea subsequently resolved at Visit 2 is noted.</description>
        <time_frame>Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
          <group group_id="O2">
            <title>Klacid SR (18 to 64 Years of Age)</title>
            <description>Participants 18 to 64 years of age.</description>
          </group>
          <group group_id="O3">
            <title>Klacid SR (65 Years of Age or Older)</title>
            <description>Participants 65 years of age or older.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnoea</title>
          <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence or absence of dyspnoea (difficulty breathing) was determined based on the clinical judgment of the treating physician and is reported for all participants and by age subgroup at Visit 1 and Visit 2. For participants with dyspnoea at Visit 1, whether the dyspnoea occurred at rest, after exercise, or both are reported. For those with dyspnoea at Visit 1, the number of participants whose original type of dyspnoea subsequently resolved at Visit 2 is noted.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
                <count group_id="O2" value="2604"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: No dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1821"/>
                    <measurement group_id="O2" value="1753"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: No dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2608"/>
                    <measurement group_id="O2" value="2451"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Dyspnoea after exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="883"/>
                    <measurement group_id="O2" value="766"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Dyspnoea after exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Dyspnoea at rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Dyspnoea at rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Both types of dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Both types of dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea resolved at Visit 2 (either type)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="799"/>
                    <measurement group_id="O2" value="710"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) After exercise dyspnoea resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="705"/>
                    <measurement group_id="O2" value="626"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Resting dyspnoea resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Auscultation Findings</title>
        <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence of abnormal breathing sounds such as wheezing or crackles was determined by the treating physician using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck, or abdomen) combined with their clinical judgment. Results are reported at Visit 1 and Visit 2 for all participants and by age subgroups. For participants with abnormal breathing sounds at Visit 1, resolution was noted at Visit 2.</description>
        <time_frame>Visit 1 (initial visit), Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
          <group group_id="O2">
            <title>Klacid SR (18 to 64 Years of Age)</title>
            <description>Participants 18 to 64 years of age.</description>
          </group>
          <group group_id="O3">
            <title>Klacid SR (65 Years of Age or Older)</title>
            <description>Participants 65 years of age or older.</description>
          </group>
        </group_list>
        <measure>
          <title>Auscultation Findings</title>
          <description>Participants were evaluated at Visit 1 (initial visit) and Visit 2 (10 to 16 days later or as defined by the treating physician). The presence of abnormal breathing sounds such as wheezing or crackles was determined by the treating physician using auscultation (listening for sounds within the body, usually with a stethoscope in the chest, neck, or abdomen) combined with their clinical judgment. Results are reported at Visit 1 and Visit 2 for all participants and by age subgroups. For participants with abnormal breathing sounds at Visit 1, resolution was noted at Visit 2.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
                <count group_id="O2" value="2604"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: Normal breath sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389"/>
                    <measurement group_id="O2" value="378"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Normal breath sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2494"/>
                    <measurement group_id="O2" value="2350"/>
                    <measurement group_id="O3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1632"/>
                    <measurement group_id="O2" value="1518"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 1: Crackles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779"/>
                    <measurement group_id="O2" value="708"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Crackles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal breath sounds resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2108"/>
                    <measurement group_id="O2" value="1974"/>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Wheezing resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1449"/>
                    <measurement group_id="O2" value="1366"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Crackles resolved at Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659"/>
                    <measurement group_id="O2" value="608"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chest Xray - Necessary for Verification of the Diagnosis of Pneumonia , Community-acquired Pneumonia</title>
        <description>Chest xrays were taken at Visit 1 to determine the presence of absence of community-acquired pneumonia. Findings are presented for all participants and by age subgroups.</description>
        <time_frame>Visit 1 (Initial visit)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
          <group group_id="O2">
            <title>Klacid SR (18 to 64 Years of Age)</title>
            <description>Participants 18 to 64 years of age.</description>
          </group>
          <group group_id="O3">
            <title>Klacid SR (65 Years of Age or Older)</title>
            <description>Participants 65 years of age or older.</description>
          </group>
        </group_list>
        <measure>
          <title>Chest Xray - Necessary for Verification of the Diagnosis of Pneumonia , Community-acquired Pneumonia</title>
          <description>Chest xrays were taken at Visit 1 to determine the presence of absence of community-acquired pneumonia. Findings are presented for all participants and by age subgroups.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
                <count group_id="O2" value="2604"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Findings did not indicate pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1742"/>
                    <measurement group_id="O2" value="1651"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Findings indicated pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1058"/>
                    <measurement group_id="O2" value="953"/>
                    <measurement group_id="O3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Previous Prescription of Other Antibiotic (Answer Whether Klacid SR is Given as the First or as Second Antibiotic)</title>
        <description>Treating physicians were asked if Klacid SR was the first or second antibiotic prescribed to treat the participant. Results are presented for all participants and age subgroups.</description>
        <time_frame>Visit 1 (Initial visit)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
          <group group_id="O2">
            <title>Klacid SR (18 to 64 Years of Age)</title>
            <description>Participants 18 to 64 years of age.</description>
          </group>
          <group group_id="O3">
            <title>Klacid SR (65 Years of Age or Older)</title>
            <description>Participants 65 years of age or older.</description>
          </group>
        </group_list>
        <measure>
          <title>Previous Prescription of Other Antibiotic (Answer Whether Klacid SR is Given as the First or as Second Antibiotic)</title>
          <description>Treating physicians were asked if Klacid SR was the first or second antibiotic prescribed to treat the participant. Results are presented for all participants and age subgroups.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
                <count group_id="O2" value="2604"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Klacid SR given as first antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2381"/>
                    <measurement group_id="O2" value="2237"/>
                    <measurement group_id="O3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klacid SR given as second antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377"/>
                    <measurement group_id="O2" value="327"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klacid SR given as third antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Response</title>
        <description>Therapeutic response (yes or no) was determined by the treating physician at Visit 2 based on the disappearance or significant alleviation of symptoms and regression of chest xray findings. The data are summarized by total number of participants and by age subgroups.</description>
        <time_frame>Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
          <group group_id="O2">
            <title>Klacid SR (18 to 64 Years of Age)</title>
            <description>Participants 18 to 64 years of age.</description>
          </group>
          <group group_id="O3">
            <title>Klacid SR (65 Years of Age or Older)</title>
            <description>Participants 65 years of age or older.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Response</title>
          <description>Therapeutic response (yes or no) was determined by the treating physician at Visit 2 based on the disappearance or significant alleviation of symptoms and regression of chest xray findings. The data are summarized by total number of participants and by age subgroups.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
                <count group_id="O2" value="2604"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Had therapeutic response to therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2786"/>
                    <measurement group_id="O2" value="2592"/>
                    <measurement group_id="O3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No therapeutic response to therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <description>The number of participants experiencing adverse events, including serious adverse events, adverse events leading to study discontinuation, or adverse events leading to a dose reduction/temporarily stopping medication are summarized. See Reported Adverse Events for additional details.</description>
        <time_frame>Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <description>The number of participants experiencing adverse events, including serious adverse events, adverse events leading to study discontinuation, or adverse events leading to a dose reduction/temporarily stopping medication are summarized. See Reported Adverse Events for additional details.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious adverse events (AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose reduced or stopped temporarily due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance (Was the Dosage and Duration of Therapy Followed or Not; if Not - Explain the Reason)</title>
        <description>Compliance was assessed by asking physicians if participants took their medication as directed. If participants did not take their medication as directed, physicians were asked to give the reason.</description>
        <time_frame>Visit 2 (10th-16th day or any other day after Inclusion Visit defined by physician)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance (Was the Dosage and Duration of Therapy Followed or Not; if Not - Explain the Reason)</title>
          <description>Compliance was assessed by asking physicians if participants took their medication as directed. If participants did not take their medication as directed, physicians were asked to give the reason.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dosage was followed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dosage was not followed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Dosage not followed due to adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Reason not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Termination of Treatment</title>
        <description>The number of participants who discontinued treatment is summarized.</description>
        <time_frame>Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
        <population>The per-protocol population was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Klacid SR (Total)</title>
            <description>All participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR.</description>
          </group>
        </group_list>
        <measure>
          <title>Termination of Treatment</title>
          <description>The number of participants who discontinued treatment is summarized.</description>
          <population>The per-protocol population was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2800"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through Visit 2 (10th-16th day or any other day after Visit 1 defined by physician)</time_frame>
      <desc>The safety analysis set was used for the analysis of safety and tolerability. The safety population consisted of all subjects who received at least one dose of Klacid SR and had final visit documentation (2800 participants).</desc>
      <group_list>
        <group group_id="E1">
          <title>Klacid SR</title>
          <description>Participants with acute tracheitis, bronchitis, or pneumonia treated with Klacid SR</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2800"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2800"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2800"/>
              </event>
              <event>
                <sub_title>Disbacteriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2800"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2800"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2800"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2800"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2800"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

